This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Libtayo
  • /
  • Study of REGN2810 in Patients With Advanced Cutane...
Clinical trial

Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma

Read time: 3 mins
Last updated:6th Apr 2016
Identifier: NCT02760498

To estimate the clinical benefit of cemiplimab monotherapy for patients with metastatic (nodal or distant) cutaneous squamous cell carcinoma (CSCC) (Groups 1 and 3) or with unresectable locally advanced CSCC (Group 2), or with advanced CSCC [metastatic (nodal or distal) or unresectable locally advanced] treated (Group 4) as measured by overall response rate (ORR), according to central review.

Study Type: Interventional  (Clinical Trial)
Estimated Enrollment: 266 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Study of REGN2810, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients With Advanced Cutaneous Squamous Cell Carcinoma
Actual Study Start Date: April 7, 2016
Estimated Primary Completion Date: February 26, 2020
Estimated Study Completion Date: August 11, 2021

- Experimental:
Group 1
- Experimental: Group 2
- Experimental: Group 3
- Experimental: Group 4

Category Value
Date last updated at source 2019-08-07
Study type(s) Interventional
Expected enrolment 266
Study start date 2016-04-07
Estimated primary completion date 2020-02-26

View full details